AzTrials
AzTrials

Esophagogastric AdenocarcinomaPhase 2NCT07507968

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

A Phase 2 study testing Durvalumab in people with Esophagogastric Adenocarcinoma, run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest at 29 sites in 2 countries.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This trial is designed to evaluate a total neoadjuvant approach using D-FLOT as the new standard backbone in patients with resectable esophagogastric adenocarcinoma. It addresses major limitations of current treatment paradigms, builds directly on the strong clinical signal from the MATTERHORN trial, and offers a… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Esophagogastric Adenocarcinoma
What is being tested?
Durvalumab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
101 participants
Where
29 sitesin 2 countries
Study dates
1 Jul 2026to 1 Feb 2030
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient* has given written informed consent
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • Patient is ≥ 18 years of age at time of signing the written informed consent
  • Patient has histologically proven locally advanced (cT2-4, any cN, M0 OR any cT, cN+, M0 stage) gastric, esophagogastric junction (type 1-3) or lower esophageal adenocarcinoma that is considered medically and technically resectable
  • Patient has a known PD-L1 status according to standardized TAP scoring (by local testing), any PD-L1 status is eligible
  • Patient has a ECOG performance status 0 or 1
Show all 18Show fewer
  • Patient must have a life expectancy of at least 12 weeks
  • Patient has adequate blood count, liver-enzymes, and renal function:
  • ANC ≥ 1.0x109 cells/L without the use of hematopoietic growth factors
  • Platelet count ≥ 75 x 109/L (>75,000 per mm3)**
  • Hemoglobin ≥ 9 g/dL**
  • Serum total bilirubin ≤ 1.5x institutional upper normal limit (ULN)
  • AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN
  • Patients not receiving therapeutic anticoagulation must have an INR ≤ 1.5 ULN and aPTT ≤ 1.5 ULN. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of inclusion.
  • Serum Creatinine ≤ 1.5 x ULN and a calculated creatinine clearance rate > 40 mL /min.
  • Patient has a body weight > 30 kg
  • Female patients defined as women of childbearing potential (WOCBP) must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for 3 months after last dose of durvalumab or 6 months after last dose of chemotherapy, whatever is later
  • Male patients with WOCBP partners must agree to remain abstinent (refrain from heterosexual intercourse) or use barrier contraceptive during the treatment period as well as up to 3 months after last dose of durvalumab or up to 6 months after last dose of chemotherapy, whatever is later. Male patients must refrain from donating sperm during this same period

Who cannot join

  • Patient received previous (radio)chemotherapy or checkpoint inhibition for the same condition or within the past five years for any other cancerous condition
  • Patient received prior partial or complete esophagogastric tumor resection
  • Patient has known hypersensitivity to any component of the durvalumab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein and/or any known contraindication (including hypersensitivity) to one of the study drugs
  • Patient has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Patient has lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within three months of the study enrolment, severe asthma, severe COPD, restrictive lung disease, relevant pleural effusion etc.)
  • Patient received a prior complete pneumonectomy
Show all 42Show fewer
  • Patient has inadequate cardiac function (LVEF value < 50 %) as determined by echocardiography
  • Patient has a known complete absence of dihydropyrimidine dehydrogenase (DPD) activity
  • Patient received treatment with brivudine, sorivudine or their chemically related analogues within 28 days prior to stud enrollment
  • Patients has pernicious anemia or other megaloblastic anemia due to vitamin B12 deficiency
  • Patient has a medical history of myocardial infarction (MI) within 6 months before enrollment, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV). Subjects with troponin levels above ULN at screening (as defined by the manufacturer), and without any MI related symptoms should have a cardiologic consultation during screening to rule out MI
  • Patient has a corrected QT interval (QTc) prolongation to > 470 ms (females) or >450 ms (males) based on average of the screening triplicate ECG
  • Patient has a history of malignancy other than EGA except for:
  • Malignancy treated with curative intent and cured with no known active disease ≥ 3 years before the first dose of study treatment and of low potential risk for recurrence.
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
  • Adequately treated carcinoma in situ without evidence of disease
  • Patient has an uncontrolled infection requiring IV antibiotics, antivirals or antifungals within 14 days prior to enrolment
  • Patient has active HBV infection, which is characterized by positive HBV surface antigen (HBsAg) and/or positive HBc antibodies (anti-HBcAb) with detectable HBV DNA (≥ 10 IU/mL or above the limit of detection per local laboratory standard), unless the participant is treated with antiviral therapy, as per institutional practice. The HBV antiviral therapy must be initiated prior to randomization, and participants must remain on antiviral therapy for the study duration and for 6 months after the last dose of response (e.g., reduction HBV DNA levels) prior to starting intervention.
  • Note: Patients who test positive for HBsAg or anti-HBc with undetectable HBV DNA (< 10 IU/mL or under the limit of detection per local laboratory standard) do not require antiviral therapy prior to enrollment. These patients are eligible and will be tested at every cycle to monitor HBV DNA levels and initiate antiviral therapy if HBV DNA is detected (≥ 10 IU/mL or above the limit of detection per local laboratory standard). The HBV DNA detectable patients must initiate and remain on antiviral therapy for the trial duration and for 6 months after the last dose of durvalumab
  • Patient has active HCV infection (as characterized by the presence of detectable HCV RNA and anti-HCV antibody [anti-HCV]) unless the patient is managed per local institutional practice for the trial and for 6 months after the last dose of durvalumab
  • Patient has any co-infection with HBV and HDV (HDV-positive infection is indicated by the presence of anti-HDV antibodies)
  • Patient has active tuberculosis infection (clinical evaluation that may include clinical history, physical examination, and radiographic findings, or tuberculosis testing in line with local practice)
  • Patient has known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled:
  • Undetectable viral RNA
  • CD4+ count ≥ 350 cells/mm3
  • No history of acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen).
  • If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended. Patient must be tested for HIV if acceptable by local regulations or an institutional IRB/IEC.
  • Patient has active or history of autoimmune disease including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener's granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. The following are exceptions to this criterion:
  • Patients with vitiligo or alopecia
  • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
  • Any chronic skin condition that does not require systemic therapy
  • Patients without active disease in the last 5 years may be included but only after consultation with the study physician
  • Patients with celiac disease controlled by diet alone
  • Patient currently or priorly used immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
  • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
  • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
  • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
  • Patient received live, attenuated vaccine within 30 days prior initiation of study drug
  • Patient has any other serious concomitant or medical condition that, in the opinion of the investigator, presents a high risk of complications to the patient or reduces the likelihood of clinical effect
  • Patient participated in another interventional clinical study within 28 days prior to study enrollment or participation in a clinical study at the same time as this study, unless it is an observational/ non-interventional study or during the follow-up period of an interventional study
  • Patient has taken an investigational drug within 28 days prior to initiation of study drug
  • Female patients, who are pregnant or breast feeding or planning to become pregnant within 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment

Trial locations and contacts

29 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Thorsten Götze, Prof. Dr. contact

+49 69 5899 787-19

d-flot-tnt@ikf-khnw.de

Kopp Christina contact

+49 69 5899 787-19

d-flot-tnt@ikf-khnw.de

29 sites in 2 countries

Germany20 sites

  • Charité Berlin

    Berlin

    Annika Kurrek, PD Dr.

  • Vivantes Klinikum Neukölln

    Berlin

    Maike de Wit, Prof. Dr.

  • Universitätsklinikum Köln

    Cologne

    Thomas Zander, Prof. Dr.

  • Klinikum Essen Mitte

    Essen

    Sebastian Ertl, Dr.

  • Krankenhaus Nordwest

    Frankfurt am Main

    Thorsten Götze, Prof. Dr.

  • Universitätsmedizin Göttingen

    Göttingen

    Ute König, Dr.

  • Universitätsklinikum Halle (Saale)

    Halle

    Ulrich Ronellenfitsch, Prof. Dr.

  • HOPE Hamburg Eppendorf

    Hamburg

    Alexander Stein, Prof. Dr.

  • UKE Hamburg

    Hamburg

    Joseph Tintelnot, Dr.

  • NCT Heidelberg

    Heidelberg

    Georg Martin Haag, Prof. Dr.

  • Marien Hospital Herne

    Herne

    Viktor Rempel, Dr.

  • Universitätsklinikum Leipzig

    Leipzig

    Getraud Stocker, Dr.

  • RKH Klinikum Ludwigsburg

    Ludwigsburg

    Angermeier Stefan, Dr.

  • Universitätsmedizin Mainz

    Mainz

    Markus Möhler, Prof. Dr.

  • Universitätsmedizin Mannheim

    Mannheim

    Ralf Hofheinz, Prof. Dr.

  • Universitätsklinikum Marburg

    Marburg

    Riera-Knorrenschild Jorge, Dr.

  • TU München

    München

    Sylvie Lorenzen, Prof. Dr.

  • Nürnberg Klinikum Nord

    Nuremberg

    Gabriele Siegler, Dr.

  • Caritas Klinikum Saabrücken

    Saarbrücken

    Jérome Schwingel, Dr.

  • Universitätsklinikum Ulm

    Ulm

    Thomas Ettrich, Dr.

Other trials in Germany

Spain9 sites

  • Hospital Universitari Germans Trias i Pujol

    Badalona

    Cristina Bugés Sánchez, Dra.

  • Hospital General Universitari Vall d'Hebron (HUVH)

    Barcelona

    Daniel Acosta Eyzaguirre, Dr.

  • Hospital Universitario Virgen de las Nieves de Granada

    Granada

    Natalia Luque Caro, Dra.

  • Hospital Regional Universitario de Jaén

    Jaén

    Dr. Francisco García Verdejo, Dr.

  • Hospital Regional Universitario de Málaga

    Málaga

    Inmaculada Ales Díaz, Dra.

  • Hospital Universitario Central de Asturias. Oncología Médica

    Oviedo

    Paula Jiménez Fonseca, Dra.

  • Hospital Universitario de Navarra (HUN)

    Pamplona

    María Alsina Maqueda, Dra.

  • Hospital Clínico Universitario de Valencia Servicio de Oncología Médica

    Valencia

    Tania Fleitas Kanonnikoff, Dra.

  • Hospital Universitario Miguel Servet Oncología Médica

    Zaragoza

    Roberto Pazo Cid, Dr.

Other trials in Spain

About this study

Official title: Total Neoadjuvant Treatment With Preoperative FLOT/Durvalumab Plus Postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma

This trial is designed to evaluate a total neoadjuvant approach using D-FLOT as the new standard backbone in patients with resectable esophagogastric adenocarcinoma. It addresses major limitations of current treatment paradigms, builds directly on the strong clinical signal from the MATTERHORN trial, and offers a rational, biologically sound framework for future therapy intensification and innovation.

By moving systemic therapy entirely into the preoperative phase, we aim to:

  • Improve patient outcomes through better adherence and deeper response
  • Minimize postoperative therapy-related dropout
  • Create a platform for rational post-surgical drug testing and individualized treatment escalation The trial will provide pivotal evidence to guide the next generation of curative-intent treatment strategies for EGA.
Read the detailed description

The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter, multi-national phase II trial. Patients with locally advanced, cT2-4 (any cN, M0) or any cT (cN+, M0), gastric, esophagogastric junction (type 1-3) or lower esophageal adenocarcinoma which are considered medically and technically resectable are eligible and will undergo baseline assessment. All patients will receive treatment consisting of up to eight 2-week cycles of FLOT chemotherapy (docetaxel 50 mg/m² IV, oxaliplatin 85 mg/m² IV, folinic acid 200 mg/m² IV, 5-FU 2,600 mg/m² IV; given on day 1 of each 2-weeks cycle [Q2W]) in combination with up to four 4-week cycles immunotherapy with durvalumab (1,500 mg IV, given on day 1 of each 4-weeks cycle [Q4W]). Four to eight weeks after last dose of preoperative treatment, patients will undergo surgical resection (tailored to the individual patient, according to local standards). Afterwards, patients will enter the maintenance phase receiving durvalumab monotherapy (1,500 mg IV, Q4W) for up to 10 cycles.

Being tested
Durvalumab
Keywords
neoadjuvant, gastric, esophageal, Durvalumab, FLOT chemotherapy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DurvalumabDrug

    Also called Imfinzi

    In the preoperative treatment phase, patients will receive eight 2-week cycles of FLOT chemotherapy (docetaxel 50 mg/m² IV, oxaliplatin 85 mg/m² IV, folinic acid 200 mg/m² IV, 5-FU 2,600 mg/m² IV; given on day 1 of each 2-weeks cycle [Q2W]). In addition, they will receive up to 4 treatments of durvalumab (1,500 mg) administrated by infusion on the first day of every second two-week cycle (Q4W).

    Four to eight weeks after the last dose of preoperative treatment, patients will undergo surgical resection. Study specifications for surgical resection are consistent with national guidelines. Surgical approaches will be tailored to the individual patient according to local standards with the goal of achieving R0-resection of the primary tumor.

    Four to twelve weeks after surgery, patients will receive durvalumab (1,500 mg IV, Q4W) monotherapy for a maximum of 10 cycles (14 cycles of durvalumab in total).

Study groups in NCT07507968
Study groupRoleWhat they receive
Durvalumab + FLOTExperimentalUp to 8x preoperative cycles FLOT plus up to 4x preoperative cycles durvalumab Followed by surgical resection Followed by postoperative durvalumab (for 10 cycles)
Receives: Drug: Durvalumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pathological complete response (pCR)

    Pathological complete response (pCR) rate as assessed locally, corresponding to the ypT0N0M0 stage category. pCR is defined as the proportion of patients with pathological complete remission in the post-surgery specimen, meaning complete absence of viable tumor cells in the primary tumor and lymph nodes and no evidence of metastatic disease upon pathological examination. For example, a patient with ypT0N0 but with pathologically confirmed peritoneal involvement containing viable tumor cells will not be considered to have achieved pCR.

    Measured: Approximately 13 months after FPI

Secondary outcomes (7)

  1. Event-free survival (EFS) plus EFS-rate at 1 year

    Event-free survival (EFS) plus EFS-rate at 1 year, defined as the time from enrollment until the date of one of the following events (whichever occurs first): progression acc. RECIST 1.1 that precludes surgery or requires non-protocol therapy during the neoadjuvant period; progression acc. RECIST 1.1 or recurrence during the adjuvant period; non-RECIST progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period or discovered during surgery; progression/recurrence confirmed by biopsy post-surgery; or death due to any cause. Patients without an event at the time of data cut-off will be censored at the date of last disease assessment.

    Measured: Approximately 13 months after FPI

  2. Event-free survival (EFS) plus EFS-rate at 2 years

    Event-free survival (EFS) plus EFS-rate at 2 years, defined as the time from enrollment until the date of one of the following events (whichever occurs first): progression acc. RECIST 1.1 that precludes surgery or requires non-protocol therapy during the neoadjuvant period; progression acc. RECIST 1.1 or recurrence during the adjuvant period; non-RECIST progression that precludes surgery or requires non-protocol therapy during the neoadjuvant period or discovered during surgery; progression/recurrence confirmed by biopsy post-surgery; or death due to any cause. Patients without an event at the time of data cut-off will be censored at the date of last disease assessment.

    Measured: Approximately 26 months after FPI

  3. Rate of patients who undergo surgery (with or without resection)

    Number of patients who were surgically resected.

    Measured: Approximately 13 months after FPI

  4. R0 resection rate

    R0 resection rate, defined as proportion of patients in whom the surgical margin is microscopically negative for residual tumor

    Measured: Approximately 13 months after FPI

  5. Assessment of postoperative ypTNM stage

    Description of ypTNM stage after surgery as assessed locally

    Measured: Approximately 13 months after FPI

  6. Overall survival (OS) plus OS-rate at 2 years

    Overall survival (OS) plus OS-rate at 2 years, defined as time from enrollment to date of death due to any cause. Patients without an event at the time of data cut-off will be censored at the last known date alive

    Measured: Approximately 26 months after FPI

  7. QoL change from baseline

    QoL change from baseline, assessed using the EORTC QLQ-C30 questionnaire based on a four-point scale. A high scale score represents a higher response level and thus a worse outcome.

    Measured: Approximately 36 months after FPI

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Apr 2026
  2. Study start1 Jul 2026 (estimated)
  3. Primary completion1 Feb 2030 (estimated)
  4. Study completion1 Feb 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
101 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07507968
Sponsor's protocol ID
IKF-099/D-FLOT-TNT
Status last verified
Mar 2026
First submitted
24 Mar 2026
Last updated
2 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No IPD will be shared

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Durvalumab in people with Esophagogastric Adenocarcinoma, run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest at 29 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 42 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 29 sites in Germany, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Thorsten Götze, Prof. Dr. (+49 69 5899 787-19, d-flot-tnt@ikf-khnw.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pathological complete response (pCR) (time frame: Approximately 13 months after FPI). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07507968.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in